Table 4.

Safety of H-1PV-based combinatorial treatments.

Tumor entity	H-1PV combination partner	Cooperative anti-neoplastic effects	Oncoselectivity	Reference
Pancreatic carcinoma	Gemcitabine	Enhanced effectiveness of combinative treatment in in vivo tumor suppression	No H-1PV-induced changes in blood-borne bone marrow activity	Angelova et al. (2009b)
			Unaffected kidney and liver functions
	VPAa	Effective H-1PV dose in vivo much reduced when VPA added to treatment	Selective tumor targeting No weight loss	Li et al. (2013)
Cervical carcinoma	VPA	Synergistic tumor growth arrest in vivo	No other signs of toxicity

^aImplantation of non-established (patient-derived) tumor material.

VPA, valproic acid.